-
1دورية أكاديمية
المؤلفون: Ascierto, PA, Dréno, B, Larkin, J, Ribas, A, Liszkay, G, Maio, M, Mandalà, M, Demidov, L, Stroyakovskiy, D, Thomas, L, de la Cruz-Merino, L, Atkinson, V, Dutriaux, C, Garbe, C, Hsu, J, Jones, S, Li, H, McKenna, E, Voulgari, A, McArthur, GA
المساهمون: Larkin, James
مصطلحات موضوعية: Antineoplastic Combined Chemotherapy Protocols, Azetidines, Follow-Up Studies, Humans, Melanoma, Mutation, Piperidines, Proto-Oncogene Proteins B-raf, Skin Neoplasms, Vemurafenib
جغرافية الموضوع: United States
وصف الملف: Print; 5235; application/pdf
العلاقة: 1078-0432.CCR-21-0809; Clinical Cancer Research, 2021, 27 (19), pp. 5225 - 5235; https://repository.icr.ac.uk/handle/internal/5284Test
الإتاحة: https://doi.org/10.1158/1078-0432.CCR-21-0809Test
https://repository.icr.ac.uk/handle/internal/5284Test -
2دورية أكاديمية
المؤلفون: Dréno, B, Ascierto, PA, Atkinson, V, Liszkay, G, Maio, M, Mandalà, M, Demidov, L, Stroyakovskiy, D, Thomas, L, de la Cruz-Merino, L, Dutriaux, C, Garbe, C, Bartley, K, Karagiannis, T, Chang, I, Rooney, I, Koralek, DO, Larkin, J, McArthur, GA, Ribas, A
المساهمون: Larkin, James
مصطلحات موضوعية: Antineoplastic Combined Chemotherapy Protocols, Azetidines, Double-Blind Method, Female, Humans, Longitudinal Studies, Male, Melanoma, Mutation, Piperidines, Placebos, Proto-Oncogene Proteins B-raf, Quality of Life, Vemurafenib
جغرافية الموضوع: England
وصف الملف: Print-Electronic; 784; application/pdf
العلاقة: bjc2017488; British Journal of Cancer, 2018, 118 (6), pp. 777 - 784; https://repository.icr.ac.uk/handle/internal/5296Test
الإتاحة: https://doi.org/10.1038/bjc.2017.488Test
https://repository.icr.ac.uk/handle/internal/5296Test -
3دورية أكاديمية
المؤلفون: Lewis, K., Robert, C., Ramella Munhoz, R., Liszkay, G., de la Cruz Merino, L., Olah, J., Queirolo, P., Mackiewicz, J., Li, H., Zhu, Q., Hertig, C., Paranthaman, N., McKenna, E.F., Gutzmer, R., McArthur, G., Ascierto, P.A.
المصدر: Annals of Oncology ; volume 33, page S917-S918 ; ISSN 0923-7534
مصطلحات موضوعية: Oncology, Hematology
الإتاحة: https://doi.org/10.1016/j.annonc.2022.07.939Test
https://api.elsevier.com/content/article/PII:S0923753422027909?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753422027909?httpAccept=text/plainTest -
4دورية أكاديمية
المؤلفون: Dummer, R., Pathan, N., Deng, S., Robert, C., Arance Fernandez, A.M., de Groot, J.W.B., Garbe, C., Gogas, H.J., Gutzmer, R., Krajsova, I., Liszkay, G., Loquai, C., Mandala, M., Schadendorf, D., Yamazaki, N., di Pietro, A., Xie, T., Ascierto, P.A., Flaherty, K.
المصدر: Annals of Oncology ; volume 33, page S902 ; ISSN 0923-7534
مصطلحات موضوعية: Oncology, Hematology
الإتاحة: https://doi.org/10.1016/j.annonc.2022.07.912Test
https://api.elsevier.com/content/article/PII:S0923753422027636?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753422027636?httpAccept=text/plainTest -
5دورية أكاديمية
المؤلفون: Ascierto, PA, Dreno, B, Larkin, J, Ribas, A, Liszkay, G, Maio, M, Mandala, M, Demidov, L, Stroyakovskiy, D, Thomas, L, de la Cruz-Merino, L, Atkinson, V, Dutriaux, C, Garbe, C, Hsu, J, Jones, S, Li, H, McKenna, E, Voulgari, A, McArthur, GA
العلاقة: pii: 1078-0432.CCR-21-0809; Ascierto, P. A., Dreno, B., Larkin, J., Ribas, A., Liszkay, G., Maio, M., Mandala, M., Demidov, L., Stroyakovskiy, D., Thomas, L., de la Cruz-Merino, L., Atkinson, V., Dutriaux, C., Garbe, C., Hsu, J., Jones, S., Li, H., McKenna, E., Voulgari, A. & McArthur, G. A. (2021). 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAF(V600) Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study. CLINICAL CANCER RESEARCH, 27 (19), pp.5225-5235. https://doi.org/10.1158/1078-0432.CCR-21-0809Test.; http://hdl.handle.net/11343/307859Test
-
6دورية أكاديمية
المؤلفون: Dummer, R., Flaherty, K.T., Robert, C., Arance, A., de Groot, J.W.B., Garbe, C., Gogas, H.J., Gutzmer, R., Krajsová, I., Liszkay, G., Loquai, C., Mandala, M., Schadendorf, D., Yamazaki, N., Zohren, F., Edwards, M., Ascierto, P.A.
المساهمون: Pfizer
المصدر: Annals of Oncology ; volume 32, page S872-S873 ; ISSN 0923-7534
مصطلحات موضوعية: Oncology, Hematology
الإتاحة: https://doi.org/10.1016/j.annonc.2021.08.1426Test
https://api.elsevier.com/content/article/PII:S0923753421036553?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0923753421036553?httpAccept=text/plainTest -
7دورية أكاديمية
المؤلفون: Ascierto P. A., Dummer R., Gogas H. J., Arance A., Mandala' M., Liszkay G., Garbe C., Schadendorf D., Krajsova I., Gutzmer R., Chiarion-Sileni V., Dutriaux C., De Groot J. W. B., Yamazaki N., Loquai C., Robert C., Flaherty K. T.
المساهمون: Ascierto, P. A., Dummer, R., Gogas, H. J., Arance, A., Mandala', M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsova, I., Gutzmer, R., Chiarion-Sileni, V., Dutriaux, C., De Groot, J. W. B., Yamazaki, N., Loquai, C., Robert, C., Flaherty, K. T.
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/37506329; info:eu-repo/semantics/altIdentifier/wos/WOS:001083390600005; volume:41; issue:29; firstpage:4621; lastpage:4631; numberofpages:11; journal:JOURNAL OF CLINICAL ONCOLOGY; https://hdl.handle.net/11391/1566833Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85169613100
-
8دورية أكاديمية
المؤلفون: Dummer R., Flaherty K. T., Robert C., Arance A., B De Groot J. W., Garbe C., Gogas H. J., Gutzmer R., Krajsova I., Liszkay G., Loquai C., Mandala' M., Schadendorf D., Yamazaki N., Pietro A. D., Cantey-Kiser J., Edwards M., Ascierto P. A.
المساهمون: Dummer, R., Flaherty, K. T., Robert, C., Arance, A., B De Groot, J. W., Garbe, C., Gogas, H. J., Gutzmer, R., Krajsova, I., Liszkay, G., Loquai, C., Mandala', M., Schadendorf, D., Yamazaki, N., Pietro, A. D., Cantey-Kiser, J., Edwards, M., Ascierto, P. A.
مصطلحات موضوعية: binimetinib, BRAF inhibitor, BRAF V600, COLUMBUS, COLUMBUS part 1, encorafenib, MEK inhibitor, melanoma, plain language summary, vemurafenib
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/37309702; info:eu-repo/semantics/altIdentifier/wos/WOS:001007802700001; volume:19; issue:16; firstpage:1091; lastpage:1098; numberofpages:8; journal:FUTURE ONCOLOGY; https://hdl.handle.net/11391/1566828Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85164209731
-
9دورية أكاديمية
المؤلفون: Lewis, K, Ascierto, P, Robert, C, Munhoz, R, Liszkay, G, De La Cruz Marino, L, Olah, J, Queirolo, P, Mackiewicz, J, Shah, K, Forbes, H, Hertig, C, Yan, Y, Gutzmer, R, McArthur, G
المصدر: 35th Anniversary Annual Meeting (SITC 2020)
العلاقة: Lewis, K., Ascierto, P., Robert, C., Munhoz, R., Liszkay, G., De La Cruz Marino, L., Olah, J., Queirolo, P., Mackiewicz, J., Shah, K., Forbes, H., Hertig, C., Yan, Y., Gutzmer, R. & McArthur, G. (2020). ATEZOLIZUMAB PLUS VEMURAFENIB AND COBIMETINIB PROVIDES FAVORABLE SURVIVAL OUTCOMES IN PATIENTS WITH HIGH TUMOR MUTATION BURDEN AND PROINFLAMMATORY GENE SIGNATURE IN THE PHASE 3 IMSPIRE150 STUDY. [Abstract]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 8 (Suppl 3), pp.A188-A189. https://doi.org/10.1136/jitc-2020-SITC2020.0307Test.; http://hdl.handle.net/11343/273968Test
-
10دورية أكاديمية
المؤلفون: Mandala, M., Arance, A., Dummer, R., Ascierto, P.A., Gogas, H., Liszkay, G., Garbe, C., Schadendorf, D., Krajsová, I., Gutzmer, R., Chiarion Sileni, V., Dutriaux, C., Loquai, C., Tadmouri, A., Pickard, M.D., Gollerkeri, A., Robert, C., Flaherty, K.T.
المصدر: Value in Health ; volume 23, page S428 ; ISSN 1098-3015
مصطلحات موضوعية: Public Health, Environmental and Occupational Health, Health Policy
الإتاحة: https://doi.org/10.1016/j.jval.2020.08.177Test
https://api.elsevier.com/content/article/PII:S1098301520324335?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S1098301520324335?httpAccept=text/plainTest
النص الكامل